AMRN - アマリン (Amarin Corporation plc) アマリン

 AMRNのチャート


 AMRNの企業情報

symbol AMRN
会社名 Amarin Corp Plc (アマリン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アマリン(Amarin Corporation plc)は心血管疾患の治療を中心とする脂質科学の専門知識を持つ後期臨床試験段階のバイオ医薬品会社。同社の製品候補「AMR101」は超高純度オメガ3脂肪酸である。同社はトリグリセリド値の高い患者または高トリグリセリド血症患者を治療するための薬品「AMR101」を開発している。平成23年9月、同社は米国食品医薬品局(FDA)に新薬承認申請(NDA)を提出した。平成23年12月、同社は「REDUCE-IT」というタイトルが付けられた「AMR101」の心血管成果試験(イコサペンタエン酸(EPA)及び心血管事故の減少という介入試験)での患者への投薬を開始した。   アマリンは英国のバイオ医薬品メ―カ―。循環器疾患の治療に焦点を当てた治療薬の研究、開発、商業化に従事。主力製品の「Vascepa」カプセルは、重度の高トリグリセリド血症の成人患者向けの治療薬で、米国食品医薬品局(FDA)の承認を取得。エイコサベンタエン酸のエチルエステルを高純度で含む。本社はアイルランド。   
本社所在地 2 Pembroke House Upper Pembroke Street 28-32 Dublin Ballsbridge 2 IRL
代表者氏名 Lars G. Ekman ラース・エックマン
代表者役職名 Independent Chairman of the Board
電話番号 +353 1-669-9020
設立年月日 32568
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 241人
url www.amarincorp.com
nasdaq_url https://www.nasdaq.com/symbol/amrn
adr_tso 291562458
EBITDA EBITDA(百万ドル) -69.12400
終値(lastsale) 18.9
時価総額(marketcap) 5510530456.2
時価総額 時価総額(百万ドル) 5215.741
売上高 売上高(百万ドル) 197.78800
企業価値(EV) 企業価値(EV)(百万ドル) 5254.872
当期純利益 当期純利益(百万ドル) -84.19700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Amarin Corporation plc (ADR) revenues increased 21% to $96.6M. Net loss increased 69% to $58.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling/General/Admin. Expense increase of 43% to $71.7M (expense) Co-promotion fees increase from $5.2M to $19.4M (expense).

 AMRNのテクニカル分析


 AMRNのニュース

   Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction - Stocks News Feed  2021/01/29 17:51:51 Stocks News Feed
Positive opinion is based on extensive clinical study results, including results of the REDUCE-IT® cardiovascular outcomes study European Commission decision on the Marketing Authorisation Application expected in April 2021 DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced that in response to Amarin’s Marketing Authorisation Application submission,… Read More »Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction
   The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa  2021/01/22 12:22:33 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 21) Acasti Pharma Inc (NASDAQ: ACST ) Alimera Sciences Inc (NASDAQ: ALIM ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Chimerix Inc (NASDAQ: CMRX ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (announced positive results for its COVID-19 antibody treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inari Medical Inc (NASDAQ: NARI ) INmune Bio Inc (NASDAQ: INMB ) ( INSM ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Inventiva ADR Representing Ord Shs (NASDAQ: IVA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Merus NV (NASDAQ: MRUS ) Neuronetics Inc (NASDAQ: STIM ) OncoSec Medical Inc (NASDAQ: ONCS ) (announced common stock offering) PRA Health Sciences Inc (NASDAQ: PRAH ) Precision BioSciences Inc (NASDAQ: DTIL ) Profound Medical Corp (NASDAQ: PROF ) Renalytix AI PLC (NASDAQ: RNLX ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Surface Oncology Inc (NASDAQ: SURF ) Syneos Health Inc (NASDAQ: SYNH ) Synlogic Inc (NASDAQ: SYBX ) Twist Bioscience Corp (NASDAQ: TWST ) Vericel Corp (NASDAQ: VCEL ) Xencor Inc (NASDAQ: XNCR ) Down In The Dumps None of the biotech/medical device/diagnostic stocks hit 52-week highs in the session.
   Stifel Nicolaus Stick to Their Hold Rating for Amarin Corporation Plc By Investing.com  2021/01/21 09:10:53 Investing.com
Stifel Nicolaus Stick to Their Hold Rating for Amarin Corporation Plc
   Amarin Provides Preliminary 2020 Results and 2021 Outlook  2021/01/07 11:05:00 GlobeNewswire
Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019 Completion of European…
   Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results - Stocks News Feed  2020/12/14 10:00:00 Stocks News Feed
REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in outpatient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability… Read More »Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results
   Amarin Provides Preliminary 2020 Results and 2021 Outlook  2021/01/07 11:05:00 GlobeNewswire
Unaudited 2020 Total Net Revenue Estimated to Be Approximately $610 Million, an Increase of Approximately 42% Compared with 2019 Completion of European…
   Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results - Stocks News Feed  2020/12/14 10:00:00 Stocks News Feed
REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in outpatient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability… Read More »Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results
   Powerful ICE: Sunday, Dec 13, 2020 (ALXN, AMRN & AXSM) - BioSci Capital Partners  2020/12/13 23:26:06 Seeking Alpha
What if I tell you that you don't need to know it all to succeed in biotech? Now, I don't mean just sitting there doing nothing. And, I don't mean you keep on waiting for luck to favor you.
   Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020  2020/12/12 21:30:00 Benzinga
VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by …
   Amarin Corporation plc (AMRN) CEO John Thero Presents at Piper Sandler 32nd Annual Virtual Healthcare Conference Call - (Transcript)  2020/12/02 17:57:07 Seeking Alpha
Amarin Corporation plc (NASDAQ:AMRN) Piper Sandler 32nd Annual Virtual Healthcare Conference Dec 02, 2020, 10:00 AM ET Company Participants John Thero - President & CEO Conference Call Participants Yasmeen Rahimi - Piper Sandler Presentation Yasmeen Rahimi Thank you for joining our live Fireside Chat with the team of Amarin Corporation.
   Powerful ICE: Sunday, Dec 13, 2020 (ALXN, AMRN & AXSM) - BioSci Capital Partners  2020/12/13 23:26:06 Seeking Alpha
What if I tell you that you don't need to know it all to succeed in biotech? Now, I don't mean just sitting there doing nothing. And, I don't mean you keep on waiting for luck to favor you.
   Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020  2020/12/12 21:30:00 Benzinga
VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by …
   Amarin Corporation plc (AMRN) CEO John Thero Presents at Piper Sandler 32nd Annual Virtual Healthcare Conference Call - (Transcript)  2020/12/02 17:57:07 Seeking Alpha
Amarin Corporation plc (NASDAQ:AMRN) Piper Sandler 32nd Annual Virtual Healthcare Conference Dec 02, 2020, 10:00 AM ET Company Participants John Thero - President & CEO Conference Call Participants Yasmeen Rahimi - Piper Sandler Presentation Yasmeen Rahimi Thank you for joining our live Fireside Chat with the team of Amarin Corporation.
   AstraZeneca – Nov 22, 2020 – Eversept Companions, LLC Buys Amarin Corp PLC, Teva Pharmaceutical Industries, Catalent  2020/11/22 07:30:00 Fintech Zoom
AstraZeneca - Nov 22, 2020 - Eversept Companions, LLC Buys Amarin Corp PLC, Teva Pharmaceutical Industries, Catalent Inc, Sells TG Therapeutics Inc, AstraZeneca PLC, Horizon Therapeutics PLC -
   Amarin Jumps on Heart-Drug Progress in China Trial  2020/11/20 15:06:04 The Street
Amarin's cardiovascular-disease treatment Vascepa met its key endpoint in a late-stage trial in China.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アマリン AMRN Amarin Corporation plc)

 twitter  (公式ツイッターやCEOツイッターなど)